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Abstract
 
Leukocyte migration is the hallmark of inflammation, and integrin 
 
a
 
M
 
b
 
2
 
 and its ligand fibrino-
gen (Fg) are key participants in this cellular response. Cells expressing wild-type or mutant
 
a
 
M
 
b
 
2
 
 and Fg or its derivatives have been used to dissect the molecular requirements for this re-
ceptor–ligand pair to mediate cell migration. The major conclusions are that (a) Fg, its D frag-
ment, and its P1 and P2 
 
a
 
M
 
b
 
2
 
 recognition peptides support a chemotactic response; (b) when
the I domain of 
 
a
 
L
 
 was replaced with the I domain of 
 
a
 
M
 
, the chimeric receptor supported cell
migration to Fg; however, the 
 
a
 
M
 
 subunit, containing the I domain but lacking the 
 
b
 
2 
 
subunit,
supported migration poorly, thus, the 
 
a
 
M
 
I domain is necessary but not sufficient to support
chemotaxis, and efficient migration requires the 
 
b
 
2
 
 subunit and 
 
a
 
M
 
I domain; and (c) in addition
to supporting cell migration, P2 enhanced 
 
a
 
M
 
b
 
2
 
-mediated chemotaxis to Fg and the P1 pep-
tide. This activation was associated with exposure of the activation-dependent epitope recog-
nized by monoclonal antibody 7E3 and was observed also with human neutrophils. Taken to-
gether, these data define specific molecular requirements for 
 
a
 
M
 
b
 
2
 
 to mediate cell migration to
Fg derivatives and assign a novel proinflammatory activity to the P2 peptide.
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Introduction
 
The leukocyte integrin 
 
a
 
M
 
b
 
2
 
 (CD11b/CD18, Mac-1,
CR3) and fibrinogen (Fg)
 
1
 
 
are key molecular participants in
the immune/inflammatory response (1–4). Within the cur-
rently accepted scenario for leukocyte trafficking during the
inflammatory reaction, 
 
a
 
M
 
b
 
2
 
 is thought to play a pivotal
role in the firm adhesion of leukocytes to the endothelium
and in the subsequent transmigration of the adherent cells to
sites of inflammation. Evidence for these functions of 
 
a
 
M
 
b
 
2
 
has been developed in studies with PMNs (5), monocytes
(6), lymphocytes (7), and eosinophils (8). The characteriza-
tion of 
 
a
 
M
 
b
 
2
 
-deficient mice has confirmed these findings by
showing that a variety of leukocyte-dependent responses are
diminished in these animals (9–11). Also, Fg is believed to
play a multifaceted role in the immune and inflammatory
response. For example, afibrinogenemic patients fail to de-
velop the induration associated with an inflammatory re-
sponse (12), depletion of mice of Fg blunts their inflamma-
tory response to biomaterial implants (4), and Fg-deficient
mice exhibit greatly reduced joint inflammation in an anti-
gen-induced arthritis model (13). Linking these two inflam-
matory/immune participants, Fg is a ligand for 
 
a
 
M
 
b
 
2
 
 (14,
15). Deposits of Fg/fibrin are adhesive for leukocytes via
 
a
 
M
 
b
 
2
 
, an interaction demonstrable in numerous in vitro and
in vivo studies (4, 16). Fg also has been shown to bridge
 
a
 
M
 
b
 
2
 
-bearing leukocytes to intercellular adhesion molecule
(ICAM)-1 on endothelial cells (17, 18). Engagement of
 
a
 
M
 
b
 
2
 
 by Fg induces a series of intracellular signaling events
and cellular responses, which are relevant to the inflamma-
tory response including cytokine secretion and nuclear fac-
tor 
 
k
 
B activation (19, 20). Most studies of Fg–
 
a
 
M
 
b
 
2
 
 interac-
tions have centered on the engagement of the molecule
with the receptor leading to cell adhesion (17, 21). How-
ever, little is known regarding the role of Fg in initiating the
diapedesis and migration of leukocytes (18, 22).
 
a
 
M
 
b
 
2
 
 is a member of the integrin family of 
 
a
 
/
 
b
 
 het-
 
erodimeric adhesion receptors and shares the same 
 
b
 
2
 
subunit as 
 
a
 
L
 
b
 
2
 
 (CD11a/CD18, LFA-1), 
 
a
 
X
 
b
 
2 
 
(CD11c/
CD18, p150,95), and 
 
a
 
D
 
b
 
2
 
 (
 
a
 
D
 
/CD18) (23–25). High af-
 
Address correspondence to Edward F. Plow, Department of Molecular
 
Cardiology (NB50), Cleveland Clinic Foundation,
 
 
 
9500 Euclid Ave./
NB50, Cleveland, OH 44195. Phone: 216-445-8200; Fax: 216-445-8204;
E-mail: plowe@ccf.org
 
1
 
Abbreviations used in this paper:
 
 Fg, fibrinogen; Fn, fibronectin; HPF,
high power field; ICAM, intercellular adhesion molecule; MIDAS, metal
ion–dependent adhesion site; NIF, neutrophil inhibitory factor; WT,
wild-type. 
1124
 
a
 
M
 
b
 
2
 
-mediated Migration to Fibrinogen Recognition Peptides
 
finity binding of many protein ligands, including Fg, to
 
a
 
M
 
b
 
2
 
 involves a segment of 
 
z
 
200 amino acids in the 
 
a
 
M
 
subunit, termed the I (or A) domain (23, 26, 27). Other I
domain ligands include ICAM-1, C3bi, 
 
Candida albicans
 
,
and the helminth protein neutrophil inhibitory factor (NIF;
references 24, 25, 28). Critical to the ligand-binding func-
tions of the 
 
a
 
M
 
 I domain is the metal ion–dependent adhe-
sion site (MIDAS). In this MIDAS motif, five noncontigu-
ous amino acids, including the D(140), S(142), S(144),
T(209), and D(242) (numbering refers to the amino acid
positions in the mature 
 
a
 
M
 
 subunit sequence), provide co-
ordination sites for a divalent cation and ligands bind in
close proximity to this motif (29, 30). Optimal recognition
of many of the 
 
a
 
M
 
 I domain ligands can be influenced by
the activation of the 
 
a
 
M
 
b
 
2
 
-bearing cell, which alters recep-
tor avidity/affinity (23, 24, 31). 
 
a
 
M
 
b
 
2
 
 recognizes mannose
and 
 
b
 
-glucan carbohydrate structures via a lectin-like
ligand-binding function. This lectin binding site is also lo-
cated in the 
 
a
 
M
 
 subunit (32). Ligands of the lectin domain
include zymosan, 
 
Saccharomyces cerevisiae
 
, and nonspecific
activators of cell-mediated immunity such as lentinan (32).
Fg is a dimeric molecule composed of three pairs of non-
identical peptide chains. It is organized into a central E and
two peripheral D domains, which give rise to E and D
fragments when Fg is degraded by most proteolytic en-
zymes, including plasmin (33). Two specific sequences
within the 
 
g
 
 chain moiety of fragment D are recognized by
 
a
 
M
 
b
 
2
 
. The peptides corresponding to these sequences are
designated P1 (
 
g
 
190–202) (34) and P2 (
 
g
 
377–395) (21).
The P1 and P2 peptides not only inhibit 
 
a
 
M
 
b
 
2
 
-mediated
adhesion to Fg derivatives but also support adhesion of
 
a
 
M
 
b
 
2
 
-bearing cells. On a molar basis, P2 is a more potent
inhibitor of 
 
a
 
M
 
b
 
2 
 
adhesion to Fg than P1 (21). The binding
sites for both the P1 and P2 peptides in 
 
a
 
M
 
b
 
2
 
 have been
mapped to the 
 
a
 
M 
 
I domain, and cells expressing the 
 
a
 
M
 
subunit in the absence of the 
 
b
 
2
 
 subunit adhere well to Fg
and these recognition peptides (21).
We have previously used HEK 293 cells transfected with
wild-type (WT) and mutant forms of 
 
a
 
M
 
b
 
2
 
 to demonstrate
the importance of the 
 
a
 
M
 
I domain for high affinity binding
of NIF (35), C3bi (36), 
 
C. albicans
 
 (37), and Fg (21, 38).
The experiments in this study describe the utilization of
these transfectants to investigate 
 
a
 
M
 
b
 
2
 
-dependent cell mi-
gration to Fg and its derivatives. We demonstrate that
 
a
 
M
 
b2 can, indeed, mediate directed cell migration to Fg
and that the recognition peptides influence this response.
Furthermore, the structural components of aMb2 that are
required for cell migration are distinct from those for cell
adhesion. Also, receptor activation is shown to play a major
role in regulating aMb2-mediated cell migration to Fg and
its derivatives. Indeed, one of the recognition peptides of
Fg is capable of inducing such activation not only in the
aMb2 transfectants but also in neutrophils.
Materials and Methods
Fg and Fibronectin Peptides. Plasminogen-depleted human Fg
was purified as described previously (39) or purchased from En-
zyme Research Laboratories. Fragment D100 (Mr 100,000) was
prepared by digestion of human Fg with plasmin and purified by
ion-exchange chromatography on CM-Sephadex followed by gel
filtration on Sephacryl S-200 (40). The Fg P1 (g190–202), P2
(g377–395), and g400–411 peptides were synthesized using an
Applied Biosystems model 430 peptide synthesizer and purified
by HPLC as described previously (21).
NIF, mAbs, and Reagents. NIF was a gift from Corvas Inter-
national. mAbs used were as follows: OKM1 (anti-CD11b,
IgG2b), 44a (anti-CD11b, IgG1), LM2/1 (anti-CD11b, IgG1),
M1/70 (anti-CD11b), IB4 (anti-CD18, IgG2a), and W6/32 (anti-
MHC class I, IgG1), TS2/18 (anti-aLb2, IgG1), and TS1/18
(anti-b2, IgG1). The hybridoma cell lines producing these mAbs
were obtained from the American Type Culture Collection and
purified from their conditioned media using recombinant protein
G columns as described by the manufacturer (Zymed Laborato-
ries). The anti-b1 mAb F4611 and anti-aVb3 mAb LM609 were
purchased from Chemicon. All of these mAbs were of mouse or-
igin, and the secondary Ab used for immunofluorescence analyses
was FITC goat anti–mouse IgG (Zymed Laboratories). c7E3, the
humanized chimeric Fab fragment, was provided by Drs. M. Na-
kada and R. Jordan of Centocor (Malvern, PA) and was labeled
with FITC (Sigma-Aldrich) according to the manufacturer’s in-
structions. b-Glucan was purchased from Molecular Probes.
Cells and Cell Lines. The HEK 293 cell lines were main-
tained as described previously (35) in DMEM-F12 plus 10% FBS,
100 U/ml penicillin, 100 mg/ml streptomycin, and 2 mM L-glu-
tamine (all from BioWhittaker). Adherent cells were removed for
passage and experiments using enzyme-free cell dissociation
buffer (GIBCO BRL). Construction of 293 cells stably expressing
WT or mutant forms of aMb2 and aLb2 has been described previ-
ously (35, 41). Before use in adhesion or cell migration assays, re-
ceptor expression levels were verified to be similar by flow
cytometry (FACS®) using a FACStar™ instrument (Becton
Dickinson). The mean fluorescent intensities for the WT and
mutants used were z300 when stained with an anti-aM mAb
(OKM1, 44a), the b2 mAb TS1/18 or TS2/18 for the aLb2 cells
compared with ,25 for mock-transfected cells. U937 monocy-
toid cells were obtained from the American Type Culture Col-
lection and maintained in RPMI 1640 with the same supple-
ments as for the HEK 293 cells. Human neutrophils were isolated
from the peripheral blood of healthy adult volunteers using Fi-
coll-Paque as per the manufacturer’s instructions (Amersham
Pharmacia Biotech) followed by dextran sedimentation and hy-
potonic lysis of residual erythrocytes as described previously (42).
The purity of the neutrophils used was routinely .96%.
Cell Migration Assays. Cell migration assays were performed
under sterile conditions using Costar 24-well transwell plates
with 8-mm pore size uncoated polycarbonate filters (Corning,
Inc.). Experiments were carried out in DMEM-F12 (BioWhit-
taker) or, for selected experiments, in hybridoma serum-free me-
dium (GIBCO BRL). Lower wells contained 600 ml medium,
whereas upper wells contained a final volume of 200 ml after the
addition of cells. To begin the assay, 50 ml of cells (5 3 105 cells)
in medium was added to upper wells, and the transwells were
placed in a humidified incubator at 378C/5% CO2. For inhibi-
tion/stimulation experiments, cells were preincubated for 30 min
at 228C with the test agents before addition to the transwells. As-
says were stopped after 22 h by removing the upper wells and
wiping the inside of upper wells twice with a cotton swab to re-
move nonmigrated cells. Quantitation of the migrated cells de-
pended on the cells under analysis. For the HEK 293 cell lines,
which remained adherent to the undersurface of the membrane,1125 Forsyth et al.
the upper transwell assembly was immersed in 10% formalin for
1 h at 228C. Cells were then stained for at least 1 h with Mayers
hematoxylin (Richard-Allan Scientific). Migrating cells were
counted using an inverted microscope with an eyepiece counting
grid at 1003 magnification. Data are presented as the mean cell
number per high power field (HPF), a 0.1-mm2 area of duplicate
wells from three or more experiments with at least five random
HPFs counted per well. Neutrophils did not adhere to the mem-
brane between the chambers but rather accumulated as a suspen-
sion in the medium in the lower chamber. These cells were
quantitated using the CyQuant Cell proliferation kit (Molecular
Probes) according to the manufacturer’s protocol. In brief, neu-
trophils within the medium of the lower chamber were recov-
ered by centrifugation, and the cells were frozen for at least 3 h at
2708C. Upon thawing, the cells were resuspended in the
CyQuant reagent, and the fluorescence was measured with a
CytoFluor II fluorescence multiwell plate reader (PerSeptive Bio-
systems, Inc.) using a 485-nm excitation and a 530-nm emission
filter. The data from these experiments are presented as the total
number of migrated cells, determined from a standard curve de-
veloped with a known amount of CyQuant-labeled cells. Data
obtained in these assays were consistent with those obtained by
microscopic counting of the neutrophils. Statistical analyses of
data from cell migration assays were performed using the Sigma-
Plot software program (Jandel) and the Student’s t test.
Results
aMb2-mediated Cell Migration to Fg. To investigate the
relationship between aMb2, Fg, and cell migration, we
compared the ability of transfected cells expressing aMb2 or
mock-transfected cells to migrate toward Fg in a transwell
system. Migration was allowed to proceed for 22 h at 378C,
at which time the cells adherent to the underside of the fil-
ter were fixed, stained, and counted. Cell viability, as
judged by trypan blue exclusion, remained high (.95%)
during the course of the assays. When the cells were placed
in the upper chamber and a Fg concentration of 50 mg/ml
in the lower chamber, a dramatic difference in the migra-
tion of the aMb2 and mock-transfected cells was observed
(Fig. 1 A). With the mock-transfected cells, 15 6 3 cells
migrated per HPF, whereas 396 6 58 of the aMb2-trans-
fected cells migrated at the same time point. Background
migration for each cell type was measured using medium
alone in lower wells. Although the number of aMb2-
expressing cells recovered on the lower surface of the filter
with only buffer present in the lower chamber was slightly
higher (59 6 9 cells/HPF) than for mock-transfected cells
(15 6 3 cells/HPF), the migration of the aMb2 cells toward
Fg was nearly sevenfold more than this background migra-
tion. Over the course of five experiments, the increase in
migration of the aMb2-transfected cells to Fg versus buffer
was 671 6 15%. Nevertheless, the mock-transfected cells
were able to migrate as demonstrated when fibronectin
(Fn) was placed in the lower wells. This migration of the
mock-transfected cells to Fn was similar in extent to that of
the aMb2-transfected cells to Fg and was inhibited by an
mAb (F4611) to the integrin b1 subunit (20 mg/ml),
which had no effect on aMb2 migration to Fg (see Fig. 1
A). These experiments were conducted in protein-free
DMEM-F12, but similar results also were obtained in hy-
bridoma serum-free medium.
Direct evidence that the migration of the transfected
cells to Fg was dependent on aMb2 was sought. Several
specific inhibitors of aMb2 function were tested for their
ability to inhibit the migration of the aMb2 transfectants to
Fg (Fig. 1 B). The test inhibitors were preincubated with
the aMb2 transfectants for 30 min before their addition to
the upper chamber of the transwell system with 50 mg/ml
Fg in the lower chamber. NIF, a high affinity ligand for the
aM I domain, eliminated migration of the aMb2 cells to Fg.
The aM I domain–specific mAb 44a also eliminated migra-
tion of the aMb2 transfectants to Fg, while a second aM
I–domain specific mAb M1/70 inhibited migration by 80%.
Figure 1. Migration of aMb2 WT transfectants but not mock transfec-
tants to Fg. Human 293 cells (5 3 105/well) expressing aMb2 (WT, black
bars) or mock-transfected cells containing only the neomycin resistance
plasmid (white bars) were assessed for their ability to migrate to Fg (50
mg/ml, 150 nM), Fn (50 mg/ml), or medium alone placed in the lower
wells of transwell plates. Some cells were pretreated with 20 mg/ml anti-
b1 blocking mAb F4611 (A) or 100 nM NIF; M1/70 and 44a, 20 mg/ml
aM-blocking mAb; IB4, 20 mg/ml b2-blocking mAb; or LM2/1, 20 mg/
ml aM-nonblocking mAb (B) for 30 min before addition to the upper
wells. Migration was assessed for 22 h at 378C and migrated cells were
fixed, stained, and counted. Migration data are expressed as mean cells/
HPF 6 SD for five random fields per well (A) or as a percentage of the
migration of the WT cells to Fg (B) with duplicate wells in each experi-
ment from three or more experiments. The x-axis indicates the addition
to the upper wells containing cells over the addition to the lower wells.
***Medium alone.1126 aMb2-mediated Migration to Fibrinogen Recognition Peptides
These results are consistent with the effects of these I do-
main mAbs on aMb2 -mediated adhesion to a variety of
ligands including Fg (26). In contrast, a nonblocking aM I
domain–specific mAb LM2/1 (26) had no effect on migra-
tion of the aMb2 transfectants. The b2-specific mAb IB4
also eliminated migration of the aMb2 transfectants to Fg.
Taken together, these results demonstrate that migration of
the transfected cells to Fg is aMb2 dependent, and agents
that block aMb2-mediated cell adhesion to Fg also block its
capacity to mediate cell migration to this ligand.
Fg as a Migratory Stimulus. In the above analyses, the
single concentration of 50 mg/ml Fg was used as a migra-
tory stimulus. As shown in Fig. 2, the extent of migration
of the aMb2-transfected cells was dependent on the avail-
able Fg concentration. Concentrations of Fg as low as 1
mg/ml induced a measurable increase in cell migration.
Maximum migration was observed at a concentration of 50
mg/ml. At a still higher dose of Fg, migration of the aMb2
transfectants decreased markedly, a pattern often encoun-
tered in such assays (43).
To investigate whether the observed aMb2 cell migration
to Fg was due to chemokinesis or chemotaxis, a checker-
board analysis was conducted. Varying concentrations of Fg
were placed either in the upper wells alone, the lower wells
alone, or both wells simultaneously (Table I). Data are pre-
sented as the percentage of migration of the aMb2 transfec-
tants to the optimal (50 mg/ml) concentration of Fg in the
lower well (% WT). With equal concentrations of Fg in
the upper and lower wells, migration of the aMb2-trans-
fected cells was only 24%, a value not significantly different
(P . 0.05) from the 15% migration with no Fg present.
With 50 mg/ml in the upper well with the cells and none
in the lower chamber, 32% of the maximal migration was
observed, suggesting that Fg may cause a modest increase in
cell motility. The chemotactic influence of Fg is supported
by the inhibition of migration to a constant concentration
of 50 mg/ml Fg in the lower well as increasing concentra-
tions of Fg were placed in the upper well: 1 mg/ml (0% in-
hibition), 10 mg/ml (35% inhibition), 50 mg/ml (76% inhi-
bition). These analyses indicate that the migration of the
aMb2 transfectants to Fg is largely directional and, there-
fore, chemotactic.
Structural Requirements within aMb2 for Cell Migration
to Fg. To investigate the role of the various domains of
aMb2 in Fg-induced cell migration, three different cell lines
expressing various forms of the receptors were examined
(Fig. 3 A). The three transfectants tested were HEK 293
cells expressing aLb2 (LFA-1), only the aM and not the b2
subunit, and the L/M mutant, an aLb2 heterodimer in
which the aL I domain was switched to the aM I domain.
All three cell lines have been characterized previously for
their ability to support adhesion to aMb2 ligands (21, 35).
All three were determined to express similar levels of re-
ceptor or the aM subunit as the WT aMb2-expressing cells
by FACS® analyses. As shown in Fig. 3 A, the aLb2-
expressing cells demonstrated no specific migration to Fg
relative to their background migration to medium alone.
The aM alone cells exhibited a weak migratory response to
Fg relative to its medium control although this level of mi-
gration was not significantly different from the background
migration of the WT transfectants to medium. These data
demonstrate a requirement for the b2 chain of the intact
heterodimer for efficient migration to Fg. Of particular
note, the L/M cells exhibited the same extent of migration
to Fg as the WT aMb2 cells, indicating the aM I domain is
sufficient to confer the migratory phenotype to the aLb2
heterodimer.
We have described previously a series of homologue
scanning mutants in which the crystal structures of I do-
mains were used as a guide to replace individual small sec-
ondary structural elements in the aM I domain with the
corresponding segment of the aL I domain in the context of
the aMb2 heterodimer expressed in the same HEK 293 cells
(35). Because of the extensive sequence and structural sim-
ilarity between the two I domains, such swaps should not
Figure 2. Migration of aMb2 transfectants to Fg. 293 cells (5 3 105/
well) expressing aMb2 (WT cells) were assessed for their ability to migrate
to various concentrations of Fg or medium alone (0 mg/ml). Migration
data are expressed as mean cells/HPF 6 SD for five random fields per well
with duplicate wells in each experiment from three or more experiments.
Table I. Fg Checkerboard Analysis
Fn concentration (upper well)
Fg concentration
(lower well) 50 mg/ml 10 mg/ml 1 mg/ml Medium only
Medium 32 18 12 16
1 mg/ml 25 18 15 29
10 mg/ml 26 29 26 58
50 mg/ml 24 65 101  100
Migration of aMb2 WT 293 transfected cells was assessed as in the legend
to Fig. 1 A to different concentrations of Fg placed either in the upper
or lower transwells. Data are means of cells per HPF for duplicate wells
from three or more experiments expressed as percentage of WT
(migration to 50 mg/ml Fg, lower well).1127 Forsyth et al.
perturb overall conformation. These mutant cell lines have
been used to map the binding sites for several aMb2 ligands
(35–38). To further dissect the role of individual segments
of the I domain in aMb2-mediated cell migration to Fg,
two representative mutant receptors were tested for their
ability to support the migratory response. Mutant P(147)-
R(152), a mutant in which the segment between these res-
idues on the MIDAS face of the I domain was switched to
the corresponding residues in aL, failed to migrate to Fg
(Fig. 3 B). This mutant also fails to recognize NIF, iC3b,
and C. albicans (35–37), indicative of the key role of this
segment in ligand recognition by aMb2, including a role in
directed cell migration. At the other extreme, mutant
Q(190)-S(197) was tested. This mutant was previously
shown to exhibit enhanced adhesion to Fg relative to the
WT aMb2 cells. However, as shown in Fig. 3 B, the migra-
tion of these cells was similar to that of WT cells, again
providing evidence that the structural requirements for ad-
hesion and migration are distinct. In view of the impor-
tance of the b2 subunit in cell migration to Fg, we also
tested the effect of single-point mutations of either D134
and S136 to alanines in the b2 subunit. These mutations re-
side at residues which are likely to serve as cation coordina-
tion sites in a MIDAS motif in integrin b subunits (44, 45),
and this MIDAS motif may be formed by an I domain–like
fold within the b subunits (46, 47). Regardless of the valid-
ity of these structural speculations, these mutations are
known to abolish ligand binding to multiple integrins (48,
49). As shown in Fig. 3 B, these mutations also abolished
the migration of the cells to Fg.
Structural Requirements within Fg for aMb2-mediated Migra-
tion. Two peptide sequences, designated P1 (g191–202)
and P2 (g373–395), in the g chain of the D domain of Fg
have been identified as aMb2 recognition sites (21, 34);
these peptides inhibit aMb2-mediated adhesion to Fg and
directly support cell adhesion via aMb2 by interacting with
the I domain of the receptor (21). Accordingly, we tested
the capacity of the D100 fragment produced by plasmin
cleavage of Fg and synthetic P1 and P2 peptides to support
aMb2-mediated cell migration. As shown in Fig. 4, the
D100 fragment of Fg supported cell migration at very low
concentrations; 1 and 10 nM concentrations of D100 were
more effective than 150 nM (50 mg/ml) Fg. The P1 and P2
peptides also supported cell migration although higher con-
centrations of the recognition peptides were required.
With P2, 3–6 mM peptide was as effective as Fg in support-
ing migration of the aMb2 transfectants. P1 was less potent
but did support a migratory response in a concentration-
dependent fashion in the 1.5–6 mM range.
Stimulation of aMb2-mediated Cell Migration by the P2 Pep-
tide of Fg. To further examine the migratory activity of
these Fg peptides, their ability to inhibit migration to Fg
and each other was assessed (Fig. 5). When placed only in
the upper well together with the cells, neither of the two
Figure 3. Migration of aMb2 WT and mutant cell lines to Fg. In A, the
cell lines are either mock-transfected or transfected cells expressing either
aMb2 WT, aLb2, aM only (expressing the aM but not b2 subunit), or L/M
chimeric (the aM I domain switched into aLb2) receptors. In B, the cell
lines are aM(P147-R152)b2, in which residues P(147)-R(152) of the aM I
domain have been switched to the corresponding residues of the aL I do-
main; aM(Q190)-S(197)b2, in which residues Q(190)-S(197) have been
switched to the corresponding residues of the aL I domain; and point mu-
tations of D(134) and S(136) to A in the b2 subunit. Details of these mu-
tations are described in reference 35. Migration of each cell type is to 50
mg/ml Fg. Data are means of cells per HPF with duplicate wells in each
experiment from three or more experiments ND expressed as the per-
centage of WT 6 SD.
Figure 4. Migration of aMb2 WT cells to Fg D100 fragment and Fg rec-
ognition peptides P1 and P2. Migration of WT cells was assessed to vari-
ous concentrations of either the Fg D100 fragment, P1 peptide, or P2 pep-
tide placed in the lower transwells. Data are means of cells per HPF with
duplicate wells for each experiment from three or more experiments and
expressed as percentage WT 6 SD.1128 aMb2-mediated Migration to Fibrinogen Recognition Peptides
peptides or the D100 fragment stimulated spontaneous mi-
gration of the aMb2 cells, suggesting that the induction of
cell migration to these derivatives was a chemotactic re-
sponse. Furthermore, when placed in equal amounts in
both the upper and lower wells, P1, P2, and the D100 frag-
ment inhibited migration to itself, consistent with a
chemotactic activity (data not shown). When testing the
effects of the Fg derivatives in influencing cell migration to
each other, some unexpected results were encountered. As
anticipated, when the P1 peptide was added to the aMb2-
transfected cells in the upper chamber, it did inhibit migra-
tion to P2 and Fg in the lower chamber. In contrast, when
P2 was added to the cells in the upper well, it stimulated
rather than inhibited migration to P1 in the lower well
(Fig. 5). To further explore the stimulatory effect of P2, its
influence on aMb2-mediated cell migration to Fg was as-
sessed. As shown in Fig. 5, when added to the cells, P2 also
stimulated migration to Fg. At a 6 mM concentration, P2
increased migration to Fg by 50% (relative to the migration
of the cells to Fg alone, 100%). In contrast, both D100 (10
nM, 82% inhibition) and P1 (6 mM, 77% inhibition) inhib-
ited migration of the aMb2 cells under the same conditions.
The Fg g400–411 peptide, reported by other investigators
to inhibit aMb2 adhesion (50) had no effect on WT migra-
tion to Fg in concentrations as high as 50 mM (data not
shown). This stimulatory effect of P2 was similar to that in-
duced by two known activators of aMb2. As shown in Fig.
6, 10 nM PMA and 2 mg/ml b-glucan were found to stim-
ulate migration by 25 and 70%, respectively. The increases
in migration induced by all three activators were statisti-
cally significant (P , 0.05) relative to the migration to Fg
in their absence. Collectively, these data demonstrate a
novel role for the P2 peptide in stimulating aMb2-mediated
migration to Fg.
We sought to determine if the activating activity of P2
on aMb2 occurs with cells other than the HEK 293 trans-
fectants. For this purpose, we tested the effects of P2 on
migration of peripheral blood neutrophils to Fg. As shown
in Fig. 7, neutrophils exhibited a substantial migratory re-
sponse to Fg, which was aMb2 dependent as indicated by
the inhibitory effect of mAb 44a. The neutrophils also mi-
grated to P2. When added to the lower wells at a 10 mM
concentration, the extent of cell migration to P2 was simi-
lar to that induced by 50 mg/ml Fg. Addition of P2 at this
concentration (or 5 mM) to neutrophils in the upper cham-
ber enhanced their migration to Fg by .50%. This incre-
ment was also aMb2 dependent as the migration was fully
inhibited by mAb 44a. Under these conditions, addition of
the same concentration P1 to the upper chamber inhibited
the migration of the neutrophils to Fg by z50% (data not
shown). Thus, P2 exerted its activating effect on a cell
which expresses aMb2 naturally.
P2 Activation of aMb2 Is Associated with Exposure of the 7E3
Epitope. To further investigate the mechanism of P2 stim-
ulation of aMb2-mediated migration to Fg, we conducted
blocking studies with the chimeric Fab fragment (abcix-
imab) of mAb 7E3. This mAb was originally developed
against integrin aIIbb3 (51) but has subsequently been
shown to interact with aVb3 and aMb2 (for a review, see
reference 52). The epitope in aMb2 resides in the I domain
and appears to require activation of the receptor for expres-
sion (53, 54). Although this mAb blocks Fg binding to the
activated aMb2 on leukocytes, it does not react with our
nonstimulated WT aMb2 transfectants as assessed by
FACS® analyses (data not shown). Based on these charac-
teristics of the 7E3 epitope, we hypothesized that c7E3
might exhibit a differential effect on nonstimulated and P2-
stimulated migration of the aMb2 transfectants to Fg. To
maximize the stimulatory effect of P2, a lower concentra-
tion of 10 mg/ml Fg was employed in the transwell migra-
Figure 5. Migration of aMb2 WT cells to Fg is inhibited by P1 but
stimulated by P2. Migration of aMb2 WT cells was assessed to various
combinations of optimal concentrations of 50 mg/ml Fg, 6 mM P1 pep-
tide, 6 mM P2 peptide, or 10 nM D100 fragment in the upper or lower
transwells as indicated. Fg or peptides added to the upper well were pre-
incubated with cells for 30 min before addition of the entire mixture to
the transwell. Data are means of cells per HPF with duplicate wells for
each experiment from three or more experiments and expressed as per-
centage of WT 6 SD.
Figure 6. Stimulation of aMb2 WT cell migration to Fg. Migration of
aMb2 WT cells to 50 mg/ml Fg was assessed in the presence of various re-
agents after preincubation for 30 min. Reagents are Fg recognition pep-
tides P1 (6 mM) or P2 (6 mM), 2 mg/ml b-glucan, and 10 nM PMA. Data
are means of cells per HPF with duplicate wells for each experiment from
three or more experiments and expressed as percentage of WT 6 SD.1129 Forsyth et al.
tion assay. As shown in Fig. 8 A, 40 mg/ml c7E3 had no
inhibitory effect on aMb2-mediated migration to Fg alone.
When 6 mM P2 was added to the cells, migration was stim-
ulated  z2.5-fold. However, when c7E3 and P2 were
added to the cells in the upper well, the increment in cell
migration was inhibited. A similar inhibitory effect of c7E3
on the migration of the aMb2-transfected cells stimulated
by b-glucan was also observed (90% inhibition; Fig. 8 A).
To rule out possible recognition of aVb3 as the basis of the
observed effects of c7E3, a potent aVb3-blocking mAb, 20
mg/ml LM609, was substituted for c7E3 and found to have
no effect on P2-stimulated (or baseline, data not shown),
aMb2-mediated cell migration to Fg. The data in Fig. 8 A
indicate that the P2 induces, not suppresses, expression of
the c7E3 epitope. We also considered whether P2 influ-
ences c7E3 reactivity with its epitope. This question was
addressed with platelets. 10 mM P2 did not inhibit the
binding of c7E3 to platelets as assessed by FACS®.
These data support a model in which an activated state of
aMb2, defined by expression of the 7E3 epitope, is induced
by P2 and supports enhanced migration to Fg. To assess this
possibility, the reactivity of the aMb2 transfectants with 7E3
was assessed by FACS® at various time points during their
migration to Fg with or without P2 present in the upper
chamber (Fig. 8 B). As noted above, the aMb2 transfectants
did not express the 7E3 epitope, and this lack of reactivity
was not changed by addition of P2 to the cells. On the
other hand, the cells developed c7E3 reactivity over time in
the presence of P2. The reactivity was noted at 1 h and in-
creased still further by 12 h (Fig. 8 B). This reactivity with
c7E3 was enhanced substantially in the presence of P2.
Discussion
Leukocyte migration is the hallmark of inflammation in
vivo, and aMb2 and Fg have been shown to contribute to
leukocyte migration in multiple systems (23, 24). This
study has used aMb2 transfectants and selected mutants to
dissect the molecular requirements for aMb2-mediated cell
migration to Fg and its derivatives. The major conclusions
of our study are the following. (a) Fg supports a chemotac-
tic cell migration mediated by aMb2. This response is de-
pendent on Fg concentration and occurs at low (1–50 mg/
ml) Fg levels. (b) The aM I domain is necessary but not suf-
ficient to support cell migration to Fg. In contrast to cell
adhesion to Fg, efficient migration requires the b2 subunit.
(c) The P1 and P2 peptides, as well as the D100 fragment,
support cell migration. Thus, the same Fg derivatives that
mediate aMb2-dependent cell adhesion also support cell
migration. (d) The P2 peptide stimulates aMb2-mediated
cell migration to Fg and the P1 peptide, in a manner similar
to other aMb2 activators, b-glucan, and PMA. In addition,
the activation-dependent epitope of c7E3 is induced by P2,
c7E3 inhibits P2, and b-glucan stimulated aMb2-mediated
migration to Fg. Many of these findings, including the acti-
vating activity of P2, are also observed in the migration of
human neutrophils to Fg. Thus, these data reveal new in-
formation regarding the molecular interactions between
Figure 7. Stimulation of neutrophil migration to Fg by P2. Isolated
human neutrophils were placed in the upper wells and 20 mg/ml Fg or 10
mM P2 in the lower wells, and migration was measured after 24 h. In the
experiments in which P2 or mAb 44a were used in the upper chambers,
these were preincubated with the neutrophils for 30 min before addition
of the cells to the upper wells. Migration data are expressed as mean cells
per HPF 6 SD for five random fields per well with duplicate wells in
each experiment from three or more experiments.
Figure 8. Role of the c7E3 epitope
in aMb2-mediated cell migration to Fg.
In A, migration of aMb2 WT cells was
assessed to a concentration of 10 mg/ml
Fg in the lower transwell. Cells were
pretreated for 30 min with peptides or
reagents before addition to the upper
transwell. Reagents are 2 mg/ml b-glu-
can, 6 mM Fg P2 peptide, 40 mg/ml
aIIbb3 mAb c7E3, 20 mg/ml aM mAb
44a, and 20 mg/ml aVb3 mAb LM609.
Data are means of cells per HPF with
duplicate wells for each experiment
from three or more experiments and ex-
pressed as percentage of WT (migration
to 10 mg/ml Fg, lower well) 6 SD. In
B, aMb2 WT cells, treated with (gray
scans) or without (white scans) P2, were
recovered from the upper wells of mi-
gration chambers at 0 (upper), 1 (mid-
dle), or 12 h (lower), stained with fluor-
escein-labeled c7E3 and analyzed by
flow cytometry.1130 aMb2-mediated Migration to Fibrinogen Recognition Peptides
aMb2 and Fg that are necessary for cell migration and de-
fine a novel mechanism whereby the P2 peptide of Fg
stimulates  aMb2-mediated chemotaxis.
More than a decade ago, Fg was identified as a ligand for
aMb2 (14), and numerous subsequent studies have exam-
ined the structure function requirements for aMb2-medi-
ated cell adhesion to Fg (38, 41). The capacity of this
ligand–receptor interaction to mediate chemotaxis has re-
ceived less attention but, in view of the propensity of Fg/
fibrin to accumulate at sites of inflammation, it is of clear
physiological relevance. Indeed, Fg and the P1 peptide
have been shown to mediate an aMb2-dependent inflam-
matory response in vivo (53, 55). Two notable in vitro
studies have also shown that Fg, as well as the D100 frag-
ment and P1 peptide, induce leukocyte transmigration and
chemotaxis which is aMb2 dependent (56, 57). Thus, the
demonstration that aMb2 transfectants migrate to Fg and its
recognition peptides is consistent with published data on
leukocytes and supports the relevance of these cells to dis-
sect the molecular requirements for the chemotactic re-
sponse. In this regard, we found that the I domain of the
receptor was not sufficient in the aM alone cells to mediate
efficient migration to Fg. However, when the aM I domain
was placed in the context of another b2 integrin, aLb2, that
does not mediate migration to Fg, chemotaxis of these L/M
cells was observed. Thus, within the context of an intact
heterodimer, the aM I domain is necessary and sufficient to
confer migration to Fg. Furthermore, within the aM I do-
main, at least some of the sequences which are key for rec-
ognition of Fg and other aMb2 ligands also influence aMb2-
mediated cell migration. Thus, the P147-152 aMb2 mutant
that fails to adhere to NIF (35), iC3b (36), C. albicans (37),
and the D100 fragment of Fg (38) also fails to migrate to Fg.
These data are consistent with results demonstrating that Fg
is a ligand for aMb2 but not aLb2, adhesion to Fg is medi-
ated principally via the I domain of aMb2, and sequences
on the MIDAS face of the aM I domain are involved in the
migratory and adhesive response of the receptor. However,
the b2 subunit is more influential in cell migration than in
cell adhesion (21). The role of the b2 subunit may depend
on the interaction of its cytoplasmic tail with cytoskeletal
elements, such as talin and paxillin, which must undergo
rearrangements in order for cells to migrate (24). Such re-
quirements for the b subunit cytoplasmic segment for mi-
gration were demonstrated with Chinese hamster ovary
cells expressing integrin aIIbb3 and migrating on Fg (58).
Integrin  aMb2-mediated migration was triggered not
only by intact Fg but also by its D100 fragment and by pep-
tides duplicating its g191–202 and g373–395 sequences.
While Fg was a potent chemoattractant, the plasmin-
derived D100 fragment was active at 150-fold lower con-
centrations. The activity of the D100 fragment and other
degradation products may be important in the recruitment
of leukocytes to inflammatory sites, where proteolysis is a
major mechanism for resolution of Fg/fibrin deposits. In
addition, fibrin(ogen) degradation products in blood could
potentially suppress leukocyte emigration. Both the P1 and
P2 peptide sequences reside in the D100 fragment. We have
found that these sequences are poorly exposed in soluble Fg
but become exposed upon its deposit or degradation (un-
published results). The combined activity and exposure of
these sequences may account for the potency of the D100
fragment as a chemoattractant. The P2 peptide was more
potent than P1 in supporting and inhibiting aMb2-depen-
dent cell migration. This difference in activity is consistent
with the greater apparent affinity of P2 for aMb2 (21).
When P2 was added to the aMb2 transfectants, it en-
hanced cell migration. This increase appears to reflect an
activation of aMb2 by the peptide. This interpretation is
supported by the observation that the epitope for c7E3,
which is expressed by activated aMb2 (53), was induced by
P2, and c7E3 inhibited the increase in cell migration
evoked by P2. The activation of integrins by peptide
ligands was originally demonstrated with aIIbb3 (59). Par-
ticularly relevant to the present observation, an aMb2
ligand peptide derived from ICAM-2 activates aMb2-medi-
ated cell migration (60). The fact that P2, but not P1, in-
duced such activation implies that, even though both pep-
tides bind to the aM I domain, they must interact in a
fundamentally different way to initiate a differential re-
sponse in the receptor. Activation of aMb2 has been shown
to be important for optimal recognition of Fg to mediate
cell adhesion (15) and migration (57). Such activation can
arise from interactions within (60) or outside of the aM I
domain (61), or outside of aMb2 altogether (PMA stimula-
tion). b-Glucan is a ligand for the lectin-binding domain of
aMb2 (61), and its activation of the receptor has been stud-
ied extensively (62). b-Glucan activation of aMb2 also is
known to result in expression of the aM I domain activa-
tion neoepitope (61) recognized by mAb CBRM1/5, and
this mAb eliminates aMb2 adhesion to Fg (63). Neverthe-
less, mAbs CBRM1/5 and c7E3 do not compete with each
other for binding to activated aMb2 (54). Our data support
a model in which b-glucan and P2 stimulation results in an
activated  aMb2 conformation, which expresses the c7E3
epitope. The greater inhibition by c7E3 of b-glucan– ver-
sus P2-stimulated migration suggests that the mechanism
and/or extent of aMb2 activation may be different. Also,
P2 was shown to enhance neutrophil migration to Fg, em-
phasizing that modulation of aMb2 function may be of
physiological significance. The g chain of Fg in which P2
resides is capable of undergoing conformational modula-
tions, including upon ligation by integrins (64). Whether
activation of the receptor via a P2-dependent mechanism is
in itself of physiological importance can only be the subject
of speculation at this time.
In summary, we have demonstrated that aMb2 can medi-
ate a chemotactic cell migration to Fg and Fg derivatives.
Both the P1 and P2 recognition peptides can support this
migratory response. Such migration depends on the aM I
domain and is influenced by other domains of aMb2. While
our earlier studies identified a negative role for the b2 sub-
unit in modulating adhesion (37), this study identifies a
positive role for the b2 subunit in influencing cell migra-
tion. Thus, the structural requirements for aMb2-mediated
cell adhesion and migration to the same ligand, Fg, are dis-1131 Forsyth et al.
tinct. In addition, we identify a novel proinflammatory
function for the P2 sequence, as well as b-glucan, to acti-
vate aMb2 and stimulate cell migration to Fg.
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